<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00883259</url>
  </required_header>
  <id_info>
    <org_study_id>12/2008</org_study_id>
    <nct_id>NCT00883259</nct_id>
  </id_info>
  <brief_title>Metformin and Gestational Diabetes in High-risk Patients: a RCTs</brief_title>
  <official_title>Metformin Treatment for Preventing Gestational Diabetes in High-risk Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Magna Graecia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Magna Graecia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gestational diabetes mellitus (DM) is one of the most frequent complications in pregnant&#xD;
      patients with polycystic ovary syndrome (PCOS) in 20-40% of cases and ~40% of patients with&#xD;
      gestational DM are likely to have underlying polycystic ovarian morphology. A recent&#xD;
      meta-analysis demonstrated a significantly higher risk of developing gestational DM [odds&#xD;
      ratio (OR) 2.94; 95% confidence interval (CI): 1.70-5.08] in the PCOS population.&#xD;
&#xD;
      Metformin is an oral biguanide insulin sensitizer used for treating type-2 DM and recently&#xD;
      introduced to treat PCOS.&#xD;
&#xD;
      At the moment, preliminary data seem to reassure regarding the use of metformin in PCOS&#xD;
      patients showing benefits for maternal and fetal outcomes, without serious adverse events.&#xD;
      Furthermore, well-designed randomized, controlled trials (RCTs) on this issue are lacking,&#xD;
      thus it is not possible to either suggest or advice against the use of metformin during&#xD;
      pregnancy for reducing gestational DM risk. To this regard, PCOS represents an intriguing&#xD;
      model of &quot;high-risk patients&quot; to evaluate the efficacy of metformin for preventing DM&#xD;
      development.&#xD;
&#xD;
      The present protocol firstly will evaluate the effects of metformin administration in&#xD;
      reducing incidence of gestational DM in high-risk patients, such as pregnant PCOS patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Obese pregnant PCOS patients with previous diagnosis of gestational DM will be enrolled and&#xD;
      allocated into two treatment arms (experimental and placebo groups). Subjects in the&#xD;
      experimental group will receive metformin at dosage of 850 mg twice daily, whereas subjects&#xD;
      in the control group will receive placebo tablets (microcristallyne cellulose) twice daily.&#xD;
&#xD;
      At baseline, all subjects will undergo clinical evaluation, serial ultrasound examinations,&#xD;
      and venous blood drawing to evaluate complete hormonal assays and serum fasting glucose and&#xD;
      insulin levels. The homeostasis model of assessment-insulin resistance, the fasting&#xD;
      glucose-to-insulin ratio, and the free androgen index will be also calculated. Monthly&#xD;
      follow-up visits will be performed for assessing maternal and fetal wellbeing.&#xD;
&#xD;
      The primary endpoint of the study will be the incidence of gestational DM. The power analysis&#xD;
      and the sample size calculation, performed using SamplePower release 2.0, showed that we will&#xD;
      need to enroll at least 40 patients for each group to yield a statistically significant&#xD;
      result with a power study of 90%. For categorical variables, the Pearson chi-square test will&#xD;
      be performed. Continuous data will be expressed either as mean and standard deviation or&#xD;
      median and inter-quartile range with min-max values, according to their normal distribution,&#xD;
      and analysed using the Student t test or Mann-Whitney U test, respectively. Statistical&#xD;
      significance will be set at P&lt;0.05. The Statistics Package for Social Science (SPSS 14.0.1;&#xD;
      Chicago, IL, USA) will be used for statistical analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2013</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of gestational DM in high-risk patients</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Abortion</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pregnancy-induced hypertension</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-eclampsia</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Macrosomia</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fetal malformations</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Premature deliveries</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrauterine deaths</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Obesity</condition>
  <condition>Polycystic Ovary Syndrome</condition>
  <condition>Gestational Diabetes</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>850 mg twice daily</description>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Microcristallyne cellulose 1 table twice daily</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women with Polycystic Ovary Syndrome (using ASRM/ESHRE criteria)&#xD;
&#xD;
          -  BMI &gt; 30&#xD;
&#xD;
          -  Previous diagnosis of gestational DM&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Major medical conditions&#xD;
&#xD;
          -  Organic pelvic diseases&#xD;
&#xD;
          -  Previous pelvic surgery&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Palomba, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics &amp; Gynecology - University Magna Graecia of Catanzaro</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francesco Orio, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Endocrinology - University &quot; Parthenope&quot; of Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Achille Tolino, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics &amp; Gynecology, University of Naples</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tommaso Simoncini, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Obstetrics &amp; Gynecology - University of Pisa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fulvio Zullo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gynecologic Unit, Cancer Center of Excellence &quot;Tommaso Campanella&quot; of Catanzaro</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefano Palomba, MD</last_name>
    <phone>+39-0961-883234</phone>
    <email>stefanopalomba@tin.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pugliese Hospital</name>
      <address>
        <city>Catanzaro</city>
        <state>Catanzaro, CZ</state>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Pugliese&quot; Hospital</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <contact>
      <last_name>Ingrid Tomaino, MD</last_name>
      <phone>+39-0961-883234</phone>
      <email>angela.falbo@libero.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Catanzaro, Italy</name>
      <address>
        <city>Catanzaro</city>
        <zip>88100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>April 16, 2009</study_first_submitted>
  <study_first_submitted_qc>April 16, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2009</study_first_posted>
  <last_update_submitted>April 5, 2013</last_update_submitted>
  <last_update_submitted_qc>April 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 8, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Magna Graecia</investigator_affiliation>
    <investigator_full_name>Stefano Palomba</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>High-risk patients</keyword>
  <keyword>Metformin</keyword>
  <keyword>PCOS</keyword>
  <keyword>Pregnancy complications</keyword>
  <keyword>Previous gestational DM</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Diabetes, Gestational</mesh_term>
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

